Anti-CD20 Bispecifics Could Find Niche In First-Line Lymphoma
Highly Entrenched Rituxan Could Prove Tough To Dislodge
Roche presented data at ASCO on its two CD20-targeting bispecific antibodies, showing high response rates in heavily pretreated non-Hodgkin lymphoma patients.
